LAVAL, QC, Nov. 30 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
today announces the departure of Philippe Calais, PhD. Pharm., Neurochem's
President, Global Business. Dr. Calais joined Neurochem in 2003, and is
leaving effective December 31, 2007, to pursue other interests.
"Dr. Calais has made a significant contribution to creating constructive
relationships for Neurochem in international markets and we are grateful for
having had the benefit of his expertise during the five years he has been with
us," said Dr. Francesco Bellini, Neurochem's Chairman, President and CEO. "We
wish him every success in his new pursuits."
Neurochem Inc. is a global health company focused on the research,
development and commercialization of products to provide innovative health
solutions to patients suffering from serious diseases.
To Contact Neurochem
For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1 877 680-4500 or
visit the Web Site at: www.neurochem.com.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's
control. Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the pharmaceutical and/or
nutraceutical industry, changes in the regulatory environment in the
jurisdictions in which Neurochem does business, stock market volatility,
fluctuations in costs, and changes to the competitive environment due to
consolidation, that actual results may vary once the final and
quality-controlled verification of data and analyses has been completed, as
well as other risks disclosed in public filings of Neurochem. Consequently,
actual future results may differ materially from the anticipated results
expressed in the forward-looking statements. The reader should not place undue
reliance, if any, on the forward-looking statements included in this news
release. These statements speak only as of the date made and Neurochem is
under no obligation and disavows any intention to update or revise such
statements as a result of any event, circumstances or otherwise. Please see
the Annual Information Form for further risk factors that might affect the
Company and its business.
For further information:
For further information: Lise Hébert, Ph.D., Vice President, Corporate
Communications, (450) 680-4572, email@example.com